PUBLISHER: The Business Research Company | PRODUCT CODE: 1946603
PUBLISHER: The Business Research Company | PRODUCT CODE: 1946603
Neurovascular embolization devices are medical tools utilized to address irregular blood vessels in the brain or central nervous system by obstructing or altering blood flow. They play a crucial role in neuro-interventional treatments aimed at addressing conditions such as aneurysms, arteriovenous malformations (AVMs), and arteriovenous fistulas (AVFs) that could lead to bleeding or other adverse outcomes.
The primary products within the category of neurovascular embolization devices comprise embolization coils, liquid embolic systems, flow diversion stents, aneurysm clips, and other related items. Embolization coils, constructed from materials such as platinum or stainless steel, are flexible devices employed to block blood flow within vessels. They are utilized in diverse treatments such as ischemic and hemorrhagic stroke solutions and are indicated for conditions such as brain aneurysms and arteriovenous malformations. These devices are utilized by various end-users including hospitals, ambulatory surgical centers, and others.
Tariffs are impacting the neurovascular embolization devices market by increasing costs of imported platinum coils, nitinol stents, microcatheters, polymers, and precision-manufactured components used in embolization systems. Hospitals and device manufacturers in North America and Europe are most affected due to reliance on specialized imported materials, while Asia-Pacific faces higher costs for device exports and component sourcing. These tariffs are raising device prices and impacting procurement budgets for neurointerventional procedures. However, they are also encouraging localized manufacturing, regional supplier partnerships, and increased investment in domestic production of high-value neurovascular devices.
The neurovascular embolization devices market research report is one of a series of new reports from The Business Research Company that provides neurovascular embolization devices market statistics, including neurovascular embolization devices industry global market size, regional shares, competitors with a neurovascular embolization devices market share, detailed neurovascular embolization devices market segments, market trends and opportunities, and any further data you may need to thrive in the neurovascular embolization devices industry. This neurovascular embolization devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The neurovascular embolization devices market size has grown strongly in recent years. It will grow from $1.38 billion in 2025 to $1.47 billion in 2026 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to rising prevalence of cerebral aneurysms, expansion of neurointerventional procedures, increasing availability of skilled neurovascular specialists, growing hospital investments in advanced neurocare, wider adoption of minimally invasive stroke treatments.
The neurovascular embolization devices market size is expected to see strong growth in the next few years. It will grow to $1.91 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to increasing demand for advanced stroke management solutions, rising investments in neurovascular R&D, expansion of aging population with vascular disorders, growing adoption of next-generation embolization devices, increasing focus on improving procedural outcomes. Major trends in the forecast period include increasing adoption of flow diversion stents, rising use of liquid embolic systems, growing preference for minimally invasive neurointerventions, expansion of coil technologies with advanced coatings, enhanced focus on precision neurovascular devices.
The increasing incidence of hemorrhages is anticipated to drive the neurovascular embolization devices market forward. Hemorrhages represent abnormal and uncontrollable bleeding occurring either internally within the body or externally through breaks in the skin or mucous membranes. Factors contributing to the prevalence of hemorrhages include aging populations, heightened occurrences of hypertension, and expanded usage of anticoagulant medications. Neurovascular embolization devices play a crucial role in managing hemorrhagic strokes by blocking abnormal blood vessels, thereby reducing bleeding and averting further brain damage. For example, recent research conducted by King's College London indicates an expected 59.4% increase in cases and deaths from intracerebral hemorrhage (a specific type of hemorrhage) among individuals aged 70 to 95 across the UK by 2050. Consequently, the mounting prevalence of hemorrhages propels the growth of the neurovascular embolization devices market.
Leading companies in the neurovascular embolization devices market are focusing on developing advanced solutions, such as next-generation flow diverters, to replace traditional aneurysm treatment methods. A next-generation flow diverter is a device designed to enhance procedural safety and effectiveness by improving vessel wall apposition, reducing clotting risk, and enabling easier deployment in complex aneurysm anatomies. For example, in July 2025, Stryker Corporation, a US-based medical technology company, launched the Surpass Elite Flow Diverter as part of its neurovascular portfolio. This innovation replaces older aneurysm treatment devices by offering minimally invasive flow diversion therapy for large or giant unruptured intracranial aneurysms. It features improved thrombo-resistance and an optimized braid design, allowing physicians to achieve better procedural outcomes with less manipulation. When integrated with Stryker's training and physician support programs, it provides a seamless clinical experience. The Surpass Elite Flow Diverter enhances patient safety, streamlines procedural workflows, and supports wider adoption of flow diversion therapy in neurovascular care.
In May 2023, Stryker Corporation, a US-based medical technology company, completed the acquisition of Cerus Endovascular Ltd for $530 million. This strategic move by Stryker was aimed at strengthening its expertise in offering innovative medical devices tailored for treating intracranial aneurysms, including products such as the contour neurovascular system and the neqstent coil-assisted flow diverter. Cerus Endovascular Ltd, headquartered in Ireland, specializes in the development of cutting-edge neurovascular embolization devices designed specifically for the treatment of intracranial aneurysms.
Major companies operating in the neurovascular embolization devices market are Johnson & Johnson, Abbott Laboratories, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, Kaneka Corporation, Terumo Corporation, B Braun Melsungen AG, Cook Medical LLC, Integer Holdings Corporation, Merit Medical Systems Inc, Penumbra Inc, Asahi Intecc Co Ltd, MicroVention Inc, Balt USA LLC, Imperative Care Inc, Acandis GmbH & Co KG, Rapid Medical Ltd, Vesalio LLC, Phenox GmbH, Cerenovus, Sequent Medical Inc
North America was the largest region in the neurovascular embolization devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurovascular embolization devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the neurovascular embolization devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The neurovascular embolization devices market consists of sales of particle embolic, detachable balloons, vascular plugs, and embolization microspheres. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Neurovascular Embolization Devices Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses neurovascular embolization devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for neurovascular embolization devices ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The neurovascular embolization devices market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.